Enfusion Considers Sale Amid Takeover Interest and Market Pressure

Enfusion, a U.S. provider of software to asset managers, is in early talks with investment bankers to evaluate strategic options, including a potential sale. The Chicago-based company, valued at $1.1 billion, began those talks after interest from private equity firms, according to sources familiar with the matter. The information remains confidential, the sources said.

While Enfusion has not formally initiated the sale process, the company could still decide to remain independent. Enfusion shares rose 19% on the news before trading was temporarily halted. The company did not immediately respond to requests for comment.

This isn’t the first time Enfusion has explored a sale. Last year, Reuters reported acquisition interest from several firms, including Francisco Partners and Vista Equity Partners. Despite efforts to attract more clients from larger funds, Enfusion shares have lost more than 50% of their value since its 2021 IPO. The company reported 16% year-over-year revenue growth in the latest quarter, falling short of market expectations.

(Based on information from the agency.)